HCQS safe and effective treatment option for Rosacea, finds study

At the end of treatment at 8 weeks, similar improvements were noted in the clinician's erythema assessment (CEA) success rates (89.28% vs 86.67%, P = .193), the investigator's global assessment (IGA) success of "clear" or "almost clear" rates (82.14% vs 93.33%, P = .555), changes in total rosacea-specific quality of life (RosaQoL) scores, and excellent improvement rate as measured by a CEA score of "clear" or "almost clear" (78.57% vs 70.00%, P = .052). Although all outcomes were similar between the two groups, noninferiority of HCQ to doxycycline was observed only in changes in RosaQoL scores.

The adverse events with HCQS were minor and included dry skin (14.3%), dry eye (7.1%) and dizziness (7.1%). At the 12-week follow-up, 4 and 3 patients reported recurrence in the HCQD and doxycycline groups, respectively.

The researchers concluded that HCQS may be an effective and safe option for rosacea. When compared with the commonly used doxycycline, advantages include safety during pregnancy and avoiding the concern for increased photosensitivity. Further investigation with a larger sample size and longer treatment duration is encouraged.

For further reference log on to: